Mustang Bio, Inc.
MBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001680048
No open-market purchases or sales by Mustang Bio, Inc. insiders were filed in the last 90 days; 23 institutions reported holding it in 13F filings for Q2 2026, worth $378.3K in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Mustang Bio, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- +2 vs. Q1 2026
- Shares held
- 539.0K
- +31.0K (+6.1%) vs. Q1 2026
- Total value
- $378.3K
- +$8.45K (+2.3%) vs. Q1 2026
- New holders
- 5
- 4 more added
- Sold out
- 3
- 1 more reduced
1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting MBIO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 23 | $378.3K |
| Q1 2026 | 22 | $369.8K |
| Q4 2025 | 25 | $541.9K |
| Q3 2025 | 20 | $426.5K |
| Q2 2025 | 17 | $70.9K |
| Q1 2025 | 16 | $142.3K |
| Q4 2024 | 30 | $826.5K |
| Q3 2024 | 25 | $207.2K |
| Q2 2024 | 29 | $372.7K |
| Q1 2024 | 30 | $798.4K |
| Q4 2023 | 28 | $1.41M |
| Q3 2023 | 27 | $1.22M |
| Q2 2023 | 28 | $3.94M |
| Q1 2023 | 52 | $3.66M |
| Q4 2022 | 66 | $4.72M |
| Q3 2022 | 70 | $6.80M |
| Q2 2022 | 77 | $10.3M |
| Q1 2022 | 85 | $25.3M |
| Q4 2021 | 88 | $46.8M |
| Q3 2021 | 83 | $71.8M |
| Q2 2021 | 98 | $85.9M |
| Q1 2021 | 99 | $80.6M |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Mustang Bio, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Kestra Advisory Services, LLC | 196,991 | $138.3K | 0.00% | +20,949+11.9% | Added |
| BlackRock, Inc. | 84,745 | $59.5K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 59,459 | $41.7K | 0.00% | +6,259+11.8% | Added |
| Geode Capital Management, LLC | 42,240 | $29.7K | 0.00% | −50,550−54.5% | Reduced |
| CFO4Life Group, LLC | 33,510 | $23.5K | 0.00% | +13,049+63.8% | Added |
| Vanguard Fiduciary Trust Co | 32,120 | $22.5K | 0.00% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 25,704 | $18.0K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 14,648 | $10.3K | 0.00% | +14,648 | New |
| Virtu Financial LLC | 14,356 | $10.0K | 0.00% | +14,356 | New |
| Two Sigma Securities, LLC | 13,742 | $9.65K | 0.00% | +13,742 | New |
| Susquehanna International Group, LLP | 13,664 | $9.59K | 0.00% | +13,664 | New |
| UBS Group AG | 4,155 | $2.92K | 0.00% | +496+13.6% | Added |
| Tower Research Capital LLC (TRC) | 1,895 | $1.33K | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 1,121 | $787 | 0.00% | +1,121 | New |
| SBI Securities Co., Ltd. | 509 | $357 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 118 | $83 | 0.00% | 00.0% | Unchanged |
| Cullen/Frost Bankers, Inc. | 13 | $9 | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 6 | $4 | 0.00% | 00.0% | Unchanged |
| NBC Securities, Inc. | 3 | $2 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 2 | $1 | 0.00% | 00.0% | Unchanged |
| Danske Bank A/S | 2 | $1 | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 1 | $1 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 2 | $1 | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −16,754−100.0% | Sold out |
| MAI Capital Management | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| CWM, LLC | – | – | – | – | Not filed |